All News

Found 56,958 articles

• Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months

  7/6/2022

  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary revenue results for the second quarter ended June 30, 2022.

• Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

  7/6/2022

  Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of patient enrollment in the Phase 2b ORIGIN clinical trial of atacicept, the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator.

• Harpoon Therapeutics Expands Leadership Team

  7/6/2022

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine.

• InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

  7/6/2022

  InflaRx N.V. today announced that the US Food and Drug Administration (FDA) granted a Fast Track designation o the development of its first-in-class anti-C5a monoclonal antibody vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG).

• Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

  7/6/2022

  Veru Inc. today announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin.

• Hemex Health and Mylab Discovery Solutions Launch Gazelle™ PathoCatch™ COVID-19 FIA Test

  7/6/2022

  Mylab Discovery Solutions, India’s leading biotechnology company, and Portland, OR-based Hemex Health, a medical diagnostic device company focused on creating diagnostics to transform frontline healthcare, announced the official launch of the Gazelle™ PathoCatch™ COVID-19 FIA test, their collaborative diagnostic solution for point-of-care (POC) testing in India.

• The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

  7/6/2022

  Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that The Lancet Gastroenterology & Hepatology published the results of the pivotal PEDFIC 1 trial, which evaluated Bylvay® (odevixibat) for the treatment of progressive familial intrahepatic cholestasis (PFIC).

• BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

  7/6/2022

  BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs.

• Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment

  7/6/2022

  Bruker Corporation (Nasdaq: BRKR) today has launched PhenoRisk PACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson.

• Sharon O'Keefe Joins Apollo Endosurgery Board of Directors

  7/6/2022

  Apollo Endosurgery, Inc. announced that Sharon O'Keefe has joined the company's Board of Directors, effective July 6, 2022.

• Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases

  7/6/2022

  Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced a poster on the ongoing international Phase 3 PHOENIX trial (study A35-004, NCT05021536) of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in people living with amyotrophic lateral sclerosis (ALS) will be presented on Saturday, July 9, at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) in Brussels, Belgium.

• BIOTRONIK's State-of-the-Art LiveSupport Successfully Used in BIOMONITOR Implantable Cardiac Monitor Implants

  7/6/2022

  BIOTRONIK's state-of-the-art LiveSupport feature was used to remotely support two BIOMONITOR Implantable Cardiac Monitor (ICM) implants shortly after launch.

• Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

  7/6/2022

  Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.

• Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

  7/6/2022

  Kamada Ltd. announced that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization, operating principally in Latin America.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2022

  7/6/2022

  AVROBIO, Inc. announced that the company has granted an aggregate of 37,500 restricted stock units to three new employees as inducement awards under the company’s 2019 Inducement Plan.

• CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

  7/6/2022

  CytomX Therapeutics, Inc. announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive /human epidermal growth factor receptor 2 -non-amplified breast cancer met its primary efficacy endpoint of confirmed objective response rate of greater than 10 percent by central radiology review.

• 9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022

  7/6/2022

  9 Meters Biopharma, Inc. announced that John Temperato, President & Chief Executive Officer of 9 Meters, will participate in a fireside chat at the William Blair Biotech Focus Conference taking place on July 12 - 13, 2022, in New York City.

• Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting - July 06, 2022

  7/6/2022

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that the Company has further adjourned its annual general and special meeting of shareholders.

• Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared

  7/6/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that the acquisition of the assets of Revo Squared LLC was recently completed.

• Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

  7/6/2022

  Avalo Therapeutics, Inc. announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022.